186 related articles for article (PubMed ID: 31947550)
41. Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor.
Langdon CG; Platt JT; Means RE; Iyidogan P; Mamillapalli R; Klein M; Held MA; Lee JW; Koo JS; Hatzis C; Hochster HS; Stern DF
Mol Cancer Ther; 2017 Jun; 16(6):1041-1053. PubMed ID: 28292938
[TBL] [Abstract][Full Text] [Related]
42. Synthesis of novel indole derivatives as promising DNA-binding agents and evaluation of antitumor and antitopoisomerase I activities.
Lafayette EA; de Almeida SMV; Cavalcanti Santos RV; de Oliveira JF; Amorim CADC; da Silva RMF; Pitta MGDR; Pitta IDR; de Moura RO; de Carvalho Júnior LB; de Melo Rêgo MJB; de Lima MDCA
Eur J Med Chem; 2017 Aug; 136():511-522. PubMed ID: 28531811
[TBL] [Abstract][Full Text] [Related]
43. Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action.
Bartscht T; Rosien B; Rades D; Kaufmann R; Biersack H; Lehnert H; Gieseler F; Ungefroren H
Mol Cancer; 2015 Nov; 14():199. PubMed ID: 26588899
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
45. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
[TBL] [Abstract][Full Text] [Related]
46. Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation.
Schwarz RE; Awasthi N; Konduri S; Caldwell L; Cafasso D; Schwarz MA
Cancer Biol Ther; 2010 Apr; 9(8):632-9. PubMed ID: 20212356
[TBL] [Abstract][Full Text] [Related]
47. Synthesis, Structure and Antiproliferative Activity of New pyrazolo[4,3- e]triazolo[4,5-b][1,2,4]triazine Derivatives.
Mojzych M; Tarasiuk P; Karczmarzyk Z; Juszczak M; Rzeski W; Fruzinski A; Wozny A
Med Chem; 2018; 14(1):53-59. PubMed ID: 29065838
[TBL] [Abstract][Full Text] [Related]
48. Synthesis and antiproliferative activity of imidazo[2,1-b][1,3,4]thiadiazole derivatives.
Kumar S; Gopalakrishnan V; Hegde M; Rana V; Dhepe SS; Ramareddy SA; Leoni A; Locatelli A; Morigi R; Rambaldi M; Srivastava M; Raghavan SC; Karki SS
Bioorg Med Chem Lett; 2014 Oct; 24(19):4682-4688. PubMed ID: 25205189
[TBL] [Abstract][Full Text] [Related]
49. Synthesis and anticancer activity of oxindole derived imidazo[1,5-a]pyrazines.
Kamal A; Ramakrishna G; Raju P; Rao AV; Viswanath A; Nayak VL; Ramakrishna S
Eur J Med Chem; 2011 Jun; 46(6):2427-35. PubMed ID: 21481986
[TBL] [Abstract][Full Text] [Related]
50. Synthesis and SAR Study of the Novel Thiadiazole-Imidazole Derivatives as a New Anticancer Agents.
Gomha SM; Abdel-Aziz HM; Khalil KD
Chem Pharm Bull (Tokyo); 2016; 64(9):1356-63. PubMed ID: 27581640
[TBL] [Abstract][Full Text] [Related]
51. Expansion of a Synthesized Library of N-Benzyl Sulfonamides Derived from an Indole Core to Target Pancreatic Cancer.
Hopkins MD; Costello IJ; Brandeburg ZC; Slay EL; Zanders LA; Dunn CE; Derewonko CA; Davitt CL; Reeder MA; Prichard K; Chiew B; McCluskey A; Sheaff RJ; Lamar AA
ChemMedChem; 2023 Oct; 18(19):e202300265. PubMed ID: 37421174
[TBL] [Abstract][Full Text] [Related]
52. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
53. Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway.
Xu XL; Yang YR; Mo XF; Wei JL; Zhang XJ; You QD
Eur J Med Chem; 2017 Sep; 137():45-62. PubMed ID: 28554092
[TBL] [Abstract][Full Text] [Related]
54. 1-Phenyl-1H-indole derivatives as a new class of Bcl-2/Mcl-1 dual inhibitors: Design, synthesis, and preliminary biological evaluation.
Xu G; Liu T; Zhou Y; Yang X; Fang H
Bioorg Med Chem; 2017 Oct; 25(20):5548-5556. PubMed ID: 28866374
[TBL] [Abstract][Full Text] [Related]
55. Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells.
Bello C; Bai J; Zambron BK; Elías-Rodríguez P; Gajate C; Robina I; Caffa I; Cea M; Montecucco F; Nencioni A; Nahimana A; Aubry D; Breton C; Duchosal MA; Mollinedo F; Vogel P
Eur J Med Chem; 2018 Apr; 150():457-478. PubMed ID: 29547833
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
Shen Q; Wang J; Liu CX; Cui W; Zhang L; Zhang YC; Wang Y; Wu J; Li JX
Eur J Med Chem; 2019 May; 170():28-44. PubMed ID: 30878830
[TBL] [Abstract][Full Text] [Related]
57. A pharmacogenomic analysis using L1000CDS
Choi EA; Choi YS; Lee EJ; Singh SR; Kim SC; Chang S
Cancer Lett; 2019 Nov; 465():82-93. PubMed ID: 31404615
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy.
Papademetrio DL; Lompardía SL; Simunovich T; Costantino S; Mihalez CY; Cavaliere V; Álvarez É
Target Oncol; 2016 Apr; 11(2):183-95. PubMed ID: 26373299
[TBL] [Abstract][Full Text] [Related]
59. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
60. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
Momeny M; Esmaeili F; Hamzehlou S; Yousefi H; Javadikooshesh S; Vahdatirad V; Alishahi Z; Mousavipak SH; Bashash D; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Haddad P; Kordbacheh F; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2019 Aug; 42(4):491-504. PubMed ID: 31025257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
